A Study of BOS-580 in Obese Subjects at Risk for Nonalcoholic Steatohepatitis (NASH)

Status:
Recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

This is a safety study to evaluate BOS-580 administered subcutaneously over 12 weeks.

Phase 2

Boston Pharmaceuticals